PCN21 Comparative Effectiveness and Cost-Effectiveness Assessment of Erlotinib Versus Gefitinib in First-Line Treatment of EGFR Activating Mutation Positive Non-Small Cell Lung Cancer for Hong Kong
Abstract
Authors
V.W.Y. Lee V. Lee B. Schwander